Abstracts tagged "Psoriatic arthritis"

Abstract Number: 2608 • ACR Convergence 2025
Metabolic dysfunction-Associated Steatotic Liver Disease, Cardiometabolic Risk Factors, and Cardiac Manifestations in Psoriasis
Maria Dons¹, Charlotte Näslund-Koch², Morten Sengeløv³, Sofie Bøgh-Sørensen³, Kristoffer Skaarup³, Marianne Bengtson Løvendorf⁴, Filip Davidovski³, Anne Marie Reimer Jensen³, Brittany Weber⁵, Lise Lotte Gluud⁶, Claus Zachariae², Lone Skov² and Tor Biering-Sørensen³, ¹Copenhagen University Hospital Gentofte, Copenhagen, Hovedstaden, Denmark, ²Dep. of Dermatology and Allergy, Copenhagen University Hospital – Herlev & Gentofte, Copenhagen, Hovedstaden, Denmark, ³Center for Translational Cardiology and Pragmatic Randomized Trials, Dep. of Cardiology, Copenhagen University Hospital - Gentofte, Copenhagen, Hovedstaden, Denmark, ⁴Department of Dermatology and Allergy, Copenhagen University Hospital – Herlev & Gentofte, Copenhagen, Hovedstaden, Denmark, ⁵Brigham and Women's Hospital, DEDHAM, MA, ⁶Gastro Unit, Copenhagen University Hospital – Hvidovre, Copenhagen, Hovedstaden, Denmark
Background/Purpose: Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognized as a cardiometabolic risk factor. Individuals with psoriasis have a high prevalence of MASLD, yet…
Abstract Number: 2357 • ACR Convergence 2025
Impact of Sonelokimab, a Novel IL-17A- and IL-17F-Inhibiting Nanobody, in Active Psoriatic Arthritis: Key Subgroup Analyses in the Randomized, Double-Blind, Placebo-Controlled Phase 2 ARGO Trial
Lihi Eder¹, Iain McInnes², Christopher Ritchlin³, Alexis Ogdie⁴, Arthur Kavanaugh⁵, Laura Coates⁶, Georg Schett⁷, Alan Kivitz⁸, Nuala Brennan⁹, Alex Godwood⁹, Matthew R. Thomas⁹, Eva Cullen⁹, Kristian Reich¹⁰, Joseph F Merola¹¹ and Philip J. Mease¹², ¹University of Toronto, Toronto, ON, Canada, ²University of Glasgow, Glasgow, United Kingdom, ³University of Rochester Medical Center, Canandaigua, NY, ⁴University of Pennsylvania, Philadelphia, PA, ⁵University of California, San Diego, School of Medicine, San Diego, CA, ⁶Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, ⁷Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ⁸Altoona Center for Clinical Research, Duncansville, PA, ⁹MoonLake Immunotherapeutics AG, Zug, Switzerland, ¹⁰MoonLake Immunotherapeutics AG and Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, Zug, Switzerland, ¹¹Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ¹²Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: PsA is a chronic inflammatory disease affecting heterogeneous tissues, with unmet need for therapies with robust efficacy across disease domains. Sonelokimab (SLK) is a…
Abstract Number: 2320 • ACR Convergence 2025
Sleep Disturbance in Psoriatic Arthritis: Prevalence by Minimal Disease Activity Status and Associated Clinical Factors
Lourdes Perez Chada¹, Vivi Feather², Grace Carter², Helen Early³, Emily Tsai², Jing Cui⁴, Avery LaChance⁵, Rochelle Castillo⁶, Neda shahriari², Alexis Ogdie⁷, Monika Haack², Elizabeth Klerman², Michael Weinblatt⁸, Nancy Shadick⁹, Joseph Merola¹⁰ and Chinmayi Naik³, ¹Harvard Medical School, Wayland, MA, ²Mass General Brigham, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham Women's Hospital, Boston, MA, ⁵Brigham and Women's Hospital, Jamaica Plain, MA, ⁶Brigham and Women's Hospital, Brookline, MA, ⁷Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Wilmington, DE, ⁸Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, ⁹Brigham & Women's Hospital, Boston, MA, ¹⁰UT Southwestern Medical Center, Dallas, TX
Background/Purpose: Sleep disturbance is a common and burdensome symptom in psoriatic arthritis (PsA), but its clinical determinants remain poorly understood. Using data from the Cohort…
Abstract Number: 1898 • ACR Convergence 2025
Assessing Representation in a Nation-Wide Psoriasis Registry: A Single-Institution Comparison
Evelyn Fagan¹, Joseph McGrath¹, Calla Sullivan¹, Mackenzie Kilton¹, Kaeli Samson², Kaleb Michaud³ and Sarah Lonowski¹, ¹University of Nebraska Medical Center Department of Dermatology, Omaha, NE, ²University of Nebraska Medical Center Department of Biostatistics, Omaha, NE, ³University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Ensuring that data registries include a representative sample is crucial for obtaining findings that can be generalized to the larger population. This comparative observational…
Abstract Number: 1458 • ACR Convergence 2025
Clinical Efficacy of Bimekizumab Treatment up to 2 Years Across Patients with Psoriatic Arthritis and Varying Baseline Joint Involvement: Results from a Post Hoc Analysis of Two Pooled Phase 3 Studies
Philip J. Mease¹, Laure Gossec², Hideto Kameda³, David Nicholls⁴, Proton Rahman⁵, Barbara Ink⁶, Rajan Bajracharya⁶, Patrick Healy⁷ and Laura Coates⁸, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France, ³Department of Internal Medicine, Toho University, Tokyo, Japan, ⁴Clinical Trials Unit, University of the Sunshine Coast, Queensland, Australia, ⁵Division of Rheumatology, Craig L. Dobbin Genetics Research Centre, Discipline of Medicine, Memorial University of Newfoundland, St. John's, Canada, ⁶UCB, Slough, England, United Kingdom, ⁷UCB, Morrisville, NC, ⁸Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom
Background/Purpose: Patients (pts) in PsA clinical trials often have greater joint involvement than in the clinical setting due to trial inclusion criteria,1 thus it is…
Abstract Number: 1425 • ACR Convergence 2025
Quantifying Functional Impact of Structural Damage in Psoriatic Arthritis: Insights from a Long-Term Prospective Cohort
Pankti Mehta¹, Shangyi Gao², Virginia Carrizo Abarza³, Fadi Kharouf⁴, Dafna D. Gladman⁵, Vinod Chandran⁶ and Denis Poddubnyy⁷, ¹University of Toronto, Gladman Krembil Psoriatic Arthritis Research Program, Toronto, ON, Canada, ²Gladman-Krembil Psoriatic Arthritis Research Program, Centre for Prognosis Studies in the Rheumatic Diseases, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, Ontario, Canada, Toronto, ON, Canada, ³University of Toronto, Toronto, ⁴University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany
Background/Purpose: Psoriatic arthritis (PsA) significantly affects physical function (PF), which is influenced by both disease activity and structural damage. Despite its clinical importance, there is…
Abstract Number: 1058 • ACR Convergence 2025
Prevalence of Depression Associated with Rheumatologic Medications with Labeled Warnings: Real World Evidence from a Tertiary Care Center
Cassandra Dolecki¹, Sama Hajizadeh¹, Yue Yin² and Adam Dore¹, ¹Allegheny Health Network, Pittsburgh, PA, ²Allegheny Health Network, Pittsburgh
Background/Purpose: The prevalence of depression in patients who have rheumatic diseases is high and has been shown to be associated with poorer outcomes. Additionally, certain…
Abstract Number: 0566 • ACR Convergence 2025
Predictor Risk Factors For Developing Difficult-to-Treat Psoriatic Arthritis in Patients Initiating a First bDMARD: a Binational Study
Astrid Goudot¹, Raphaël Hurtubise², Eugénie Robin³, Laurine Cadart⁴, Raghav Ramachandran⁵, Federica Re⁵, Tristan Pascart⁶, Cécile Philippoteaux⁷, René-Marc Flipo⁷, Laura Coates⁸ and Jean-Guillaume Letarouilly¹, ¹Université de Lille, CHU Lille, Service de rhumatologie, Lille, France, Lille, Nord-Pas-de-Calais, France, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK., Oxford, United Kingdom, ³CH Valenciennes, Service de rhumatologie, Valenciennes, France, Valenciennes, France, ⁴Service de biostatistiques, CHU Lille, Lille, France, Lille, France, ⁵Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, UK, Oxford, United Kingdom, ⁶GHICL, Hôpital Saint-Philibert, Service de rhumatologie, Lomme, France, Lomme, France, ⁷Université de Lille, CHU Lille, Service de rhumatologie, Lille, France, Lille, France, ⁸Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom
Background/Purpose: Risk factors to identify patients who will develop a difficult-to-treat (D2T) psoriatic arthritis (PsA) are still lacking when initiating a first bDMARD. There are…
Abstract Number: 0546 • ACR Convergence 2025
Multimorbidity clusters in psoriatic arthritis, psoriasis, and axial spondyloarthritis and their association with healthcare utilization: A population-based study
Paras Karmacharya¹, Dilli Poudel², Daniel Shin³, Robert Fitzsimmons³, Leslie Crofford⁴ and Alexis Ogdie⁵, ¹Vanderbilt University, Nashville, TN, Hermitage, TN, ²Vanderbilt University Medical Center, Nashville, TN, ³University of Pennsylvania, Philadelphia, ⁴Vanderbilt University Medical Center, Melbourne, AR, ⁵University of Pennsylvania, Philadelphia, PA
Background/Purpose: Multimorbidity (≥ 2 chronic conditions) is common in inflammatory diseases such as psoriatic arthritis (PsA), psoriasis (PsO), and axial spondyloarthritis (AxSpA), increasing patient burden…
Abstract Number: 0371 • ACR Convergence 2025
Lifestyle Coaching in Psoriatic Arthritis: Pilot Findings from an Online eCoaching Program
Judy Zhang¹, Leonard Calabrese², Shilpa Venkatachalam³, angela Degrassi⁴, Yuxuan Jin² and M. Elaine Husni⁵, ¹Cleveland Clinic, Cleveland, United States, Cleveland, OH, ²Cleveland Clinic, Cleveland, OH, ³Global Healthy Living Foundation, New York, NY, ⁴Global Healthy Living Foundation, Upper Nyack, NY, ⁵Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH
Background/Purpose: As healthcare shifts towards patient-centered care, multifactorial lifestyle interventions, though effective, often impose time and resource burdens on patients. An online program like IMMUNE…
Abstract Number: 2609 • ACR Convergence 2025
Evaluation of the Performance of Candidate Enthesitis Ultrasound Scoring Systems for Psoriatic Arthritis Diagnosis – DUET Study
Nam Nguyen¹, Mu Yang², Sibel Aydin³, Gurjit Kaeley⁴, Richard Cook² and Lihi Eder¹, ¹University of Toronto, Toronto, ON, Canada, ²University of Waterloo, Waterloo, Canada, ³Department of Medicine, University of Ottawa, The Ottawa Hospital Research Institute, Ottawa, ON, Canada, ⁴UF COM-J, Ponte Vedra Beach, FL
Background/Purpose: Psoriatic arthritis (PsA) is often diagnosed late, leading to worse outcomes. Enthesitis is a key feature that can aid in early detection, but its…
Abstract Number: 2358 • ACR Convergence 2025
Bimekizumab Demonstrated Early and Sustained Efficacy Regardless of Baseline Characteristics in Patients with Active Psoriatic Arthritis: Pooled Post Hoc Results up to 1-Year from Two Phase 3 Studies
Lihi Eder¹, Philip J. Mease², Iain McInnes³, M. Elaine Husni⁴, Mitsumasa Kishimoto⁵, Barbara Ink⁶, Rajan Bajracharya⁶, Jason Coarse⁷ and Fabian Proft⁸, ¹University of Toronto, Toronto, ON, Canada, ²Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ³University of Glasgow, Glasgow, United Kingdom, ⁴Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁵Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, ⁶UCB, Slough, England, United Kingdom, ⁷UCB, Morrisville, NC, ⁸Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
Background/Purpose: Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17F in addition to IL‑17A, has demonstrated clinical efficacy and safety to 3 years…
Abstract Number: 2317 • ACR Convergence 2025
Cardiovascular Risk and Psoriatic Arthritis Features: Dactylitis may Predict Cardiovascular Events
Roel Sanchez Baez¹, Katherine Benson¹, Arthur Kavanaugh² and Monica Guma¹, ¹University of California, San Diego, La Jolla, CA, ²Division of Rheumatology, Autoimmunity and Inflammation, UC San Diego School of Medicine, La Jolla, CA
Background/Purpose: Patients with PsA have an elevated risk of cardiovascular (CV) disease. We assessed whether specific PsA features may predict CV events among PsA patients.Methods:…
Abstract Number: 1883 • ACR Convergence 2025
Temporal Patterns of Cardiometabolic Comorbidities Before and After Psoriatic Arthritis Diagnosis: A Nationwide Retrospective Study from Poland.
Batko Bogdan¹, Mateusz Szeląg², Krzysztof Batko³, Magdalena Krajewska-Włodarczyk⁴, Zbigniew Żuber⁵, Marcin Stajszczyk⁶, Brygida Kwiatkowska⁷ and Tomasz Guzik⁸, ¹Department of Rheumatology and Immunology, Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski University, Krakow, Poland, Kraków, Poland, ²Ministry of Health, Warsaw, Poland, ³Department of Dermatology, University Hospital in Krakow, Poland, Krakow, Poland, ⁴University of Warmia & Mazury, Olsztyn, Poland, ⁵Department of Pediatrics, Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski University, Krakow, Poland, Krakow, Poland, ⁶Department of Rheumatology and Autoimmune Diseases, Silesian Center for Rheumatology, Orthopedics and Rehabilitation, Ustroń, Poland, Ustron, Poland, ⁷Clinic of Early Arthritis, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland, Warsaw, Poland, ⁸BHF Centre for Research Excellence, Centre for Cardiovascular Sciences, The University of Edin-burgh, Edinburgh, UK, Edinburgh, United Kingdom
Background/Purpose: While the association between psoriatic arthritis (PsA) and cardiometabolic disorders is established, the temporal sequence and progression of these comorbidities remain poorly characterized. To…
Abstract Number: 1457 • ACR Convergence 2025
Real-world Patient Trajectories in Psoriasis and Psoriatic Arthritis: a Retrospective Study
Philip J. Mease¹, Qi Wei², Lawrence Huang³, Jason Hawkes⁴, Clive Liu⁵, Ying Wu⁶, Tony Wang⁷, Anthony Hager⁸ and Jennifer Hadlock³, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²Institute for Systems Biology, Seattle, WA, ³Institute for Systems Biology, Seattle, ⁴Oregon Medical Research Center, Portland, OR, ⁵Bellevue Dermatology, Bellevue, ⁶Bristol Myers Squibb, Princeton, NJ, ⁷Bristol Meyers Squib, Princeton, NJ, ⁸Bristol Myers Squibb, Seattle, WA
Background/Purpose: Real world data from community healthcare systems can provide insights into patient trajectories with psoriasis (PsO) and psoriatic arthritis (PsA): baseline characteristics, patterns of…

1
2
3
…
93
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].